Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)のEPS
March 2025 時点のEPS TTM: $-0.73
Regulus Therapeutics Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-0.73です。2023年末には、EPSは$-1.58で、2022年のEPS$-1.86と減少でした。
Regulus Therapeutics Inc.のEPS履歴(2010から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-0.73 -10.98%
2024 $-0.82 -48.10%
2023 $-1.58 -15.05%
2022 $-1.86 -42.59%
2021 $-3.24 -28.00%
2020 $-4.50 -58.22%
2019 $-10.77 -80.72%
2018 $-55.87 -32.67%
2017 $-82.98 -55.37%
2016 $-185.94 42.90%
2015 $-130.12 -15.65%
2014 $-154.27 164.98%
2013 $-58.22 -77.11%
2012 $-254.37 -92.84%
2011 $-3.55K -51.14%
2010 $-7.27K 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -2,472.60%
US
$27.74 -3,900.00%
NL
$-7.98 993.15%
US
$-5.29 624.66%
AU
- -
CH